European Renal Association

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Retrieved on: 
Monday, March 25, 2024
MD, LOS, ERA, European Renal Association, Patient, Kidney disease, Congress, Nephrology, Therapy

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.

Key Points: 
  • LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.
  • Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494.
  • In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress.
  • We look forward to participating in this important event.”

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024
CMC, LOS, Dialysis, Patient, Therapy, International Society of Nephrology, NKF, National Kidney Foundation, ATP, Agency, Hyperphosphatemia, American Journal, Acute kidney injury, Nephrology, Clutch (eggs), ISN, Trial of the century, Society, Kidney disease, Chronic kidney disease, Water, NDA, European Renal Association, HIV/AIDS, CKD, Conditional sentence, Heart, FDA, Tablet, ERA, Letter, Patent, International Society, Mitochondrial disease, Diabetes, Physician, Pharmaceutical industry

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Serum albumin, ALC, European Renal Association, MMF, Itolizumab, Safety, Ono Pharmaceutical, Dialysis, Type, Children's Organ Transplant Association, Patient, Bruce Steel, American College of Rheumatology, Novel, American College, Therapy, Lupus nephritis, Standard of care, ORR, Infection, Partnership, EGFR, CD6, S1P, EULAR, AMP, ACR, Trial of the century, Proteinuria, Pharmaceutical industry, Silviculture, Nursing, UPCR, Medicine, Lupus

“It’s important that we saw both early and large reductions in proteinuria,” said Dr.

Key Points: 
  • “It’s important that we saw both early and large reductions in proteinuria,” said Dr.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.
  • The poster presentation is available on the Presentations page of Equillium’s website under the Lupus tab.

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Retrieved on: 
Monday, November 6, 2023
Oncology, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, EOS, Type, EULAR, Patient, Standard of care, Lupus nephritis, Itolizumab, III, EGFR, Therapy, AMP, Children's Organ Transplant Association, CD6, Infection, Society, American Society of Nephrology, European Alliance of Associations for Rheumatology, European Renal Association, Dialysis, ASN, Partnership, MMF, ORR, ALC, S1P, Ono Pharmaceutical, Safety, Serum albumin, Proteinuria, Pharmaceutical industry, Silviculture, Nursing, Lupus, UPCR

“The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.

Key Points: 
  • “The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.
  • “We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
COL7, G&A, Cystic fibrosis, Congress, Investigational New Drug, Patient, R, Disease, MYC, Research, Concha bullosa, Alport syndrome, Proteinuria, Cystic Fibrosis Foundation, MAD, COL, Rare, FDA, IND, COL4A4, Collagen, Kidney failure, Skin, Natural history, European Renal Association, Glomerular basement membrane, Cancer, Ultrafiltration, Fibroblast, Colorectal cancer, Radar, Podocyte, Familial adenomatous polyposis, Clinical trial, SAD, FAP, Large intestine, RNA, Trial of the century, Keratinocyte, APC, Food, UPCR, Pharmaceutical industry, Vaccine, Dietary supplement, Health insurance, Alport, RDEB, Creatinine

Podocytes are specialized cells that bind to the glomerular basement membrane and form finger-like extensions called foot processes that enable efficient ultrafiltration.

Key Points: 
  • Podocytes are specialized cells that bind to the glomerular basement membrane and form finger-like extensions called foot processes that enable efficient ultrafiltration.
  • Podocyte injury leads to the effacement (loss) of podocyte foot processes and proteinuria in nearly all cases of Alport syndrome.
  • An IND application for ELX-02 is expected to be submitted to the FDA in the third quarter of 2023.
  • Eloxx remains focused on its liquidity position and is committed to raising additional capital in the near term in order to fund its operating plan through the end of 2023 and beyond.

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Injection, Insurance, Duke Energy, Kidney failure, Chronic kidney disease, European Renal Association, Clinical trial, REACT, SGLT2, Dialysis, ERA, Congress, Patient, Kidney, Biostatistics, Research, CKD, Safety, D, Pharmaceutical industry, EU

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Around the end of 2023, we are also planning to report on the progress of participants in our open-label Phase 2 REGEN-007 study of REACT.
  • That study is designed to elicit visibility into the potential kidney outcomes of our commercial stage REACT formulation when injected into both kidneys.
  • ProKidney expects to commence enrollment in the second half of 2023 with initial interim data expected by the end of 2025.

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Total, KCR, European Renal Association, Autoimmune hepatitis, Week, Cohort, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, National Kidney Foundation, ALT, KZR, EULAR, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Vaccine, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • The complete MISSION Phase 1b/2 results were presented as an oral presentation at the LUPUS & KCR 2023 meeting, which took place May 17-20, 2023 in Seoul, Korea.
  • Research and development expenses for the second quarter of 2023 increased by $9.7 million to $21.0 million compared to $11.3 million in the second quarter of 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 increased by $0.8 million to $5.8 million compared to $5.0 million in the second quarter of 2022.

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Retrieved on: 
Thursday, August 10, 2023
European Renal Association, EGFR, Glomerular filtration rate, Period. End of Sentence., Vera, ERA, Proteinuria, Congress, Patient, Therapy, Pharmaceutical industry, Cryptocurrency, IgA nephropathy

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the second quarter ended June 30, 2023.
  • “During the second quarter, we announced positive 36-week data from the Phase 2b ORIGIN trial, which support its potential as a disease-modifying treatment for patients with IgAN,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.
  • During the six months ended June 30, 2023, net cash used in operating activities was $44.1 million, compared to $28.0 million for the same period last year.
  • Vera reported $181.0 million in cash, cash equivalents, and marketable securities as of June 30, 2023.

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Pharmaceutical, Health, Patent, MMF, SG, POT, European Renal Association, Marketing, PSF, Bank statement, Nephrology, AURORA, Conversation, J.P. Morgan & Co., Risk, EDGAR, LN, ERA, Proteinuria, European Alliance of Associations for Rheumatology, Orange Book, Arthritis & Rheumatology, Patient, Investment, Analysis, SEDAR, Rheumatology, Webcast, United Kingdom, Management, Growth, EULAR, R, Research, FDA, NICE, National Institute for Health and Care Excellence, Cryptocurrency, Pharmaceutical industry, Clothing, Aurinia, Swissmedic

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.
  • Financial Results for the Three and Six Months Ended June 30, 2023
    Total net revenue was $41.5 million and $28.2 million for the three months ended June 30, 2023 and June 30, 2022, respectively.
  • Interest expense was $0.1 million for the three and six months ended June 30, 2023 due to the commencement of the monoplant finance lease during the second quarter of 2023.
  • Aurinia will host a conference call and webcast to discuss the quarter ended June 30, 2023 financial results today, Thursday, August 3, 2023 at 8:30 a.m.

ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension

Retrieved on: 
Friday, July 14, 2023
Health, FDA, Medical Devices, Health Technology, Pharmaceutical, Cardiology, Biotechnology, Blood pressure, CE, European Renal Association, Food, ReCore, SOLO, RDN, ERA, Journal, PMA, Patient, European Society for Medical Oncology, International Society on Hypertension in Blacks, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, International Society, Pharmaceutical industry, Medicine, Hypertension

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.

Key Points: 
  • ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.
  • The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
  • Current rates of treatment and control of hypertension remain suboptimal, and the ESH guidelines assist clinicians and patients in achieving the goal of better health.
  • “Recommendation of renal denervation by the recently published European Society of Hypertension (ESH) 2023 Guidelines is a significant milestone for the field of arterial hypertension management.